• Publications
  • Influence
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
TLDR
It is demonstrated that each H3F3A mutation defines an epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive with IDH1 mutations, which characterize a third mutation-defined subgroup. Expand
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
TLDR
The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. Expand
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
TLDR
The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma, and the glucocorticoid requirement was lower. Expand
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
TLDR
Evidence is provided for a previously unidentified pathophysiological function of the AHR that is constitutively generated by human tumours via tryptophan-2,3-dioxygenase (TDO), a liver- and neuron-derived Trp-degrading enzyme not yet implicated in cancer biology. Expand
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
TLDR
An inverse association of IDH1 and IDH2 mutations of the R132C type are strongly associated with astrocytoma, while IDH 2 mutations predominantly occur in oligodendroglial tumors. Expand
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
TLDR
This study provides first clinical evidence for the implication of a "glioma stem cell" or "self-renewal" phenotype in treatment resistance of glioblastoma. Expand
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
TLDR
The data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas is reviewed and ongoing studies that are testing resistance-modulating strategies are described. Expand
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
TLDR
IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation and associated with prolonged PFS in the chemotherapy and radiotherapy arm. Expand
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
TLDR
Temozolomide alone is non-inferior to radiotherapy alone in the treatment of elderly patients with malignant astrocytoma and MGMT promoter methylation seems to be a useful biomarker for outcomes by treatment and could aid decision-making. Expand
Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt
TLDR
An invitro model of hypoxic neuroprotection in cerebellar granule neurons is developed and a sequential requirement for VEGF/VEGFR-2 activation and Akt/PKB phosphorylation for neuronal survival mediated by hypoxic preconditioning is indicated and V EGF is proposed as a hypoxia-induced neurotrophic factor. Expand
...
1
2
3
4
5
...